Rodgers R J, Cole J C, Davies A
Department of Psychology, University of Leeds, UK.
Pharmacol Biochem Behav. 1994 Aug;48(4):959-63. doi: 10.1016/0091-3057(94)90205-4.
Flesinoxan is a potent and selective 5-HT1A receptor agonist. In this study, the effects of this compound on behavior in the murine elevated plus-maze have been assessed using a recently developed ethological scoring method. Results show that, at low doses (0.1-0.5 mg/kg), flesinoxan inhibited risk assessment behaviors (stretched attend postures and closed arm returns) indicative of a reduction in anxiety. These effects were maintained at a higher dose of 1.0 mg/kg, which also increased percent open entries and time spent on the central platform and open arms. However, this more convincing anxiolytic profile was associated with significant reductions in total arm entries and rearing, suggesting a combination of anxiolysis and behavioral suppression at high doses. The plus-maze profile observed with flesinoxan is very similar to that previously reported for 8-OH-DPAT in the same test but, despite superficial similarities, can be distinguished from that seen with buspirone. Data are discussed in relation to behavioral similarities and differences between 5-HT1A receptor agonists, and the advantages of a more detailed approach to the analysis of plus-maze behavior.
氟司必宁是一种强效且具有选择性的5-羟色胺1A受体激动剂。在本研究中，已使用最近开发的行为学评分方法评估了该化合物对小鼠高架十字迷宫行为的影响。结果显示，在低剂量（0.1 - 0.5毫克/千克）时，氟司必宁抑制了表明焦虑减轻的风险评估行为（伸展关注姿势和返回封闭臂）。这些效应在1.0毫克/千克的较高剂量下得以维持，该剂量还增加了进入开放臂的百分比以及在中央平台和开放臂上花费的时间。然而，这种更具说服力的抗焦虑特征与总臂进入次数和竖毛行为的显著减少相关，表明高剂量时存在抗焦虑和行为抑制的组合。在相同测试中，氟司必宁观察到的十字迷宫特征与先前报道的8-羟基二丙胺基四氢萘非常相似，但尽管表面相似，却可与丁螺环酮所见的特征区分开来。讨论了有关5-羟色胺1A受体激动剂之间行为异同的数据，以及对十字迷宫行为进行更详细分析方法的优势。
